Institutional investors purchased a net $39.7 million shares of GILD during the quarter ended September 2016 and now own 78.24% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
ANTIPODES PARTNERS LTD. Bought 633.2 Thousand shares of Gilead Sciences
NNIP ADVISORS BV Bought 272.0 Thousand shares of Gilead Sciences